Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to Strong-Buy at Raymond James

Raymond James upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) to a strong-buy rating in a report published on Wednesday morning, Zacks.com reports. Eupraxia Pharmaceuticals Price Performance Shares of EPRX opened at $2.85 on Wednesday. Eupraxia Pharmaceuticals has a 12-month low of $2.48 and a 12-month high of $6.78. Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get […]

Related Keywords

Raymond James , Eupraxia Pharmaceuticals , Eupraxia Pharmaceuticals Inc , News Ratings For Eupraxia Pharmaceuticals Daily , Eupraxia Pharmaceuticals Price Performance , Eupraxia Pharmaceuticals Company Profile , Free Report , Get Free Report , Pharmaceuticals Inc , Eupraxia Pharmaceuticals Daily ,